Patents Represented by Attorney Ronald G. Ort
-
Patent number: 5578283Abstract: A catalyst and process for treating gas streams which contain halogenated organic compounds, non-halogenated organic compounds, carbon monoxide or mixtures thereof, and particularly gas streams which contain organobromides. The catalyst comprises at least one platinum group metal, zirconium oxide and at least one oxide of manganese, cerium or cobalt.Type: GrantFiled: December 30, 1994Date of Patent: November 26, 1996Assignee: Engelhard CorporationInventors: James M. Chen, Pascaline H. Nguyen
-
Patent number: 5262168Abstract: A liposome composition and methods for making same are disclosed, such compositions comprise an arachidonic acid metabolite such as a prostaglandin, preferably prostaglandin E.sub.1, a lipid, and a drying protectant such as a saccharide. The liposomes may be loaded with prostaglandin passively, or using a transmembrane concentration gradient, preferably using a transmembrane pH gradient. Using this transmembrane loading technique, trapping efficiencies of 50% to 100% are achieved, and the release rate of the prostaglandin from the liposomes is reduced. The liposome size is maintained after lyophilization and reconstitution.Type: GrantFiled: January 16, 1992Date of Patent: November 16, 1993Assignee: The Liposome Company, Inc.Inventors: Robert P. Lenk, Michelle L. Tomsho, Robert L. Suddith, Robert J. Klimchak
-
Patent number: 5169637Abstract: A new and substantially improved type of lipid vesicle, called stable plurilamellar vesicles (SPLVs), are described, as well as the process for making the same and X-ray diffraction methods for identifying the same. SPLVs are characterized by lipid bilayers enclosing aqueous compartments containing one or more entrapped solutes, the concentration of such solutes in each aqueous compartment being substantially equal to the emunization of solutes used to prepare the SPLVs. The bilayers of SPLVs are substantially non-compressed. SPLVs are stable during storage and can be used in vivo for the sustained release of compounds and in the treatment of disease.Type: GrantFiled: April 2, 1991Date of Patent: December 8, 1992Assignee: The Liposome Company, Inc.Inventors: Robert P. Lenk, Michael W. Fountain, Andrew S. Janoff, Mircea C. Popescu, Steven J. Weiss, Richard S. Ginsberg, Marc J. Ostro, Sol M. Gruner
-
Patent number: 5100662Abstract: The present invention relates to novel liposomes and liposome-like structures (vesicles) comprising an amount of a derivatized sterol either alone or in combination with additional liposome-forming lipids.Sterols such as cholesterol or other lipids, to which numerous charged or neutral groups are attached, may be used to prepare liposomes and liposome-like structures such as micelles, reverse micelles and hexagonal phases, suspensions of multilamellar vesicles or small unilamellar vesicles. The novel liposomes of the present invention may be prepared with or without the use of organic solvents. These vesicles may entrap compounds varying in polarity and solubility in water and other solvents.Type: GrantFiled: October 16, 1989Date of Patent: March 31, 1992Assignee: The Liposome Company, Inc.Inventors: Lois E. Bolcsak, Lawrence Boni, Mircea C. Popescu, Paul A. Tremblay
-
Patent number: 5082664Abstract: A liposome composition and methods for making same are disclosed, such compositions comprise an arachidonic acid metabolite such as a prostaglandin, preferably prostaglandin E.sub.1, a lipid, and a drying protectant such as a saccharide. The liposomes may be loaded with prostaglandin passively, or using a transmembrane concentration gradient, preferably using a transmembrane pH gradient. Using this transmembrane loading technique, trapping efficiencies of 50% to 100% are achieved, and the release rate of the prostaglandin from the liposomes is reduced. The liposome size is maintained after lyophilization and reconstitution.Type: GrantFiled: May 18, 1988Date of Patent: January 21, 1992Assignee: The Liposome Company, Inc.Inventors: Robert P. Lenk, Michelle L. Tomsho, Robert L. Suddith, Robert J. Klimchak
-
Patent number: 5030453Abstract: A new and substantially improved type of lipid vesicle, called stable plurilamellar vesicles (SPLVs), are described, as well as the process for making the same and X-ray diffraction methods for identifying the same. SPLVs are characterized by lipid bilayers enclosing aqueous compartments containing one or more entrapped solutes, the concentration of such solutes in each aqueous compartment being substantially equal to the concentration of solutes used to prepare the SPLVs. The bilayers of SPLVs are substantially non-compressed. SPLVs are stable during storage and can be used in vivo for the sustained release of compounds and in the treatment of disease.Type: GrantFiled: October 12, 1984Date of Patent: July 9, 1991Assignee: The Liposome Company, Inc.Inventors: Robert P. Lenk, Michael W. Fountain, Andrew S. Janoff, Mircea C. Popescu, Steven J. Weiss, Richard S. Ginsberg, Marc J. Ostro, Sol M. Gruner
-
Patent number: 5026557Abstract: An adjuvant composition comprising a small liposome with incubation associated immuno-potentiator such as Lipid A, said composition with incubation associated antigen, and method of preparation and use.Type: GrantFiled: February 14, 1990Date of Patent: June 25, 1991Assignee: The Liposome Company, Inc.Inventors: Leonard Estis, Phillip Livingston
-
Patent number: 5008050Abstract: A method for reducing the lamellarity of a population of liposomes is provided which comprises repeatedly passing the liposomes under pressure through a filter which has a pore size equal to or less than about 100 nm. In certain embodiments, the method is used to convert a population of previously formed multilamellar liposomes into a population of substantially unilamellar liposomes. In accordance with other aspects of the disclosure, liposomes are prepared directly from a lipid powder or pellet and buffer without the use of any solvents, detergents or other extraneous materials.Type: GrantFiled: February 13, 1989Date of Patent: April 16, 1991Assignee: The Liposome Company, Inc.Inventors: Pieter R. Cullis, Michael J. Hope, Marcel B. Bally
-
Patent number: 5000958Abstract: The invention encompasses mixtures of antimicrobial agents coencapsulated in liposomes which when administered in vivo exert an enhanced therapeutic effect. The therapeutic effectiveness of the coencapsulated antimocrobial agents is greater than that of the same combination administered either in solution or as a mixture of liposome populations each containing one of the antimicrobial agents.Type: GrantFiled: July 26, 1984Date of Patent: March 19, 1991Assignee: The Liposome Company, Inc.Inventors: Michael W. Fountain, Steven J. Weiss, Robert P. Lenk, Mircea C. Popescu, Richard S. Ginsberg
-
Patent number: 4981692Abstract: A method of treating, by intramammary infusion of liposomes, Brucella spp. infections in an animal by administration of a therapeutically effective amount of aminoglycoside in liposome form, also being a method of administering a therapeutic agent in liposome form to a proximal mammary lymph node or mammary tissue of an animal.Type: GrantFiled: August 18, 1987Date of Patent: January 1, 1991Assignee: The Liposome Company, Inc.Inventors: Mircea Popescu, Christine E. Swenson, Sterling C. Johnson, Robert P. Lenk
-
Patent number: 4891480Abstract: An electrical device is provided which has contacts having regions with a conductive matte-finish metal surface. The matte-finish surface is characterized by having a Knoop hardness number of at least 300, a diffuse reflectance of less than about 20 percent, and a specular reflectance of less than about 2 percent. These contacts have a contact resistance of less than about 50 milliohms, under a 50-gram load, even after exposure to 50.degree. C. and 95% relative humidity for a period of 20 days. Reflection electron microscopy shows that particularly advantageous matte-finish surfaces have sharply peaked asperities with average peak angles of less than about 90 degrees. In one embodiment, the surface is formed of hardened nickel electroplated from an electrolytic bath with a pH above about 7.0.Type: GrantFiled: February 1, 1989Date of Patent: January 2, 1990Assignee: American Telephone and Telegraph Company, AT&T Bell LaboratoriesInventors: Clarence A. Holden, Jr., Henry H. Law
-
Patent number: 4835437Abstract: Light output of single crystal phosphors used on cathode ray tubes can be vastly improved by use of a microfaceted surface structure conveniently produced by use of a single crystal epitaxial layer with lattice constant slightly larger than the single crystal substrate. Such epitaxial layers are conveniently grown using substituents that increase the lattice constant compared to the single crystal substrate.Type: GrantFiled: May 16, 1988Date of Patent: May 30, 1989Assignee: American Telephone and Telegraph Company, AT&T Bell LaboratoriesInventors: George W. Berkstresser, Charles D. Brandle, Jr.
-
Patent number: 4594356Abstract: A method of inducing short-term pupil diameter enlargement and reducing intraocular pressure in animals without significant systemic effects is disclosed. There is provided a site-specific chemical delivery method for topically applying to the eye of an animal, an effective ophthalmologically acceptable amount of an adrenalone diester of the general formula: ##STR1## wherein R prepresents a member selected from the group consisting of hydrogen or a C.sub.1 -C.sub.3 straight alkyl group; and wherein R.sub.1 and R.sub.2 independently represent an acyl group or derivative thereof; or an opthalmologically acceptable acid addition salt thereof. The method allows the pupil diameter to be enlarged for a short period after which the pupil returns to normal and thus restores normal eye sight.Type: GrantFiled: January 8, 1985Date of Patent: June 10, 1986Assignee: Key Pharmaceuticals, Inc.Inventor: Nicholas Bodor
-
Patent number: 4587118Abstract: A dry sustained release oral dosage formulation of theophylline and a method of orally administering theophylline is disclosed. The oral formulation is comprised of a capsule which includes upper and lower parts which are connectible and easily separable from each other, and a plurality of micropellets present in the capsule. The micropellets provide sustained release of theophylline when taken by a patient and are comprised of inner seeds coated with a mixture of theophylline and polyvinylpyrrolidone which is further coated with a mixture of ethylcellulose and hydroxypropylcellulose. The oral dosage formulation is administered by separating the upper and lower parts of the capsule and placing the micropellets on a food which is preferably soft to the extent of not requiring chewing and then eating the food with the micropellets thereon.Type: GrantFiled: December 12, 1984Date of Patent: May 6, 1986Assignee: Key Pharmaceuticals, Inc.Inventor: Chiin H. Hsiao
-
Patent number: 4297399Abstract: A composition and process for improving the curing of concrete, the composition comprising a Singapore dammar resin dissolved in an organic solvent. In a preferred embodiment of this invention, the resin-solvent solution is dispersed in a water-based emulsion by the use of an appropriate emulsifying agent. A preferred organic solvent is mineral spirits, and preferably the organic solvent contains a low enough level of photochemically reactive liquids to meet air pollution requirements such as Los Angeles Rule 66.Type: GrantFiled: January 8, 1980Date of Patent: October 27, 1981Assignee: Martin Marietta CorporationInventor: John S. Perz
-
Patent number: 4270393Abstract: A vibration-isolating apparatus having orthogonal X, Y, and Z axes is provided for mounting a payload to a base. The payload contains a torque producing device. Torque generated about the X-axis in the payload is communicated to the base through a stiff linkage in the rotational degree of freedom about the X-axis. The apparatus includes first and second support frames, the payload mounted on the first support frame and the second support frame mounted to the base. Gimbal means permit rotation of the payload about the Y and Z axes. Linear dampening means dampen forces between the payload and base communicated linearly along the X, Y and Z axes and rotation dampening means dampen forces between the payload and base communicated rotationally about the Y and Z axes.Type: GrantFiled: March 12, 1979Date of Patent: June 2, 1981Assignee: Martin Marietta CorporationInventors: Norman A. Osborne, Robert L. Gates
-
Patent number: 4239788Abstract: A process for forming a delineated vapor deposition film of a deposition material on a substrate. The delineation is accomplished by exposing selected areas of the substrate to an electron beam before depositing the deposition material whereby the sticking coefficients of the selected areas are sufficiently reduced so as to prevent any significant deposition in those areas. Furthermore, irradiated areas of the substrate can be restored to their original surface characteristics by exposure to a second electron beam while the substrate is at an elevated temperature. Thus, areas of the substrate can be negatively delineated to prevent deposition, and such negatively delineated surfaces can then be positively delineated to permit deposition.Type: GrantFiled: June 15, 1979Date of Patent: December 16, 1980Assignee: Martin Marietta CorporationInventor: William A. Beck
-
Patent number: 4224076Abstract: A method is provided for improving the strength and other properties of non-plastic dry hydraulic cement mixes, such as the dry concrete mixes used for making concrete masonry units. The method comprises incorporating a synergistic combination of two additives into the cement mix. The first additive is a salified methyl or ethyl substituted benzene or naphthalene sulfonate, and is preferably added in an amount of between about 0.01 and 1%, by weight based upon the weight of the cement. The second additive is a tertiary aliphatic amine oxide, and is preferably added in an amount of between 0.001 and 0.1%.Type: GrantFiled: December 11, 1978Date of Patent: September 23, 1980Assignee: Martin Marietta CorporationInventors: Santanu Moitra, Philip A. Rosskopf
-
Patent number: 4168984Abstract: Improved hydraulic cement mixes are made by incorporating into such mixes an admixture comprising at least one acetic acid ester of a glycol in an amount sufficient to increase the compressive strength of products made from such mixes. In portland-type cement mixes, these admixtures also act as set accelerators. In high-alumina cement mixes, the admixtures not only increase strength but also inhibit the spontaneous loss of strength which is generally characteristic of high-alumina cements. A preferred admixture is ethylene glycol diacetate in an amount of up to about 3.0% by weight based upon the weight of the cement, preferably in an amount of between about 0.01% and 2.0% by weight.Type: GrantFiled: February 9, 1978Date of Patent: September 25, 1979Assignee: Martin Marietta CorporationInventor: James A. Ray
-
Patent number: 4135941Abstract: An improved process for producing portland and portland type cement clinker wherein argillaceous and calcareous type materials are ground and blended to form a generally homogeneous mixture and subsequently burned in a kiln at a temperature in the range of about 1200.degree. C. to about 1500.degree. C. to form cement clinker, the improvement comprising incorporating into the mixture a fluorine containing mineral acid, selected from the group comprising fluotitanic acid, fluoboric acid, fluophosphoric acid, fluosilicic acid, and hydrofluoric acid, as a fluxing and mineralizing agent, in an amount of up to 3.0% by weight based upon the weight of the dry solids in the mixture.Type: GrantFiled: April 25, 1977Date of Patent: January 23, 1979Assignee: Martin Marietta CorporationInventors: Jan P. Skalny, Waldemar A. Klemm